Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase

Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediate...

Full description

Saved in:
Bibliographic Details
Main Authors BEMBENEK, SCOTT D, ECCLES, WENDY, GOMEZ, LAURENT, SANTILLAN, JR, BACANI, GENESIS, MCCLURE, KELLY J, MIRZADEGAN, TARANEH, GRICE, CHERYL A, EDWARDS, JAMES P, KEARNEY, AARON M, EPPERSON, MATTHEW T, LEE-DUTRA, ALICE, LANDRY-BAYLE, ADRIENNE M
Format Patent
LanguageChinese
English
Published 01.08.2009
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atheroscierosis and prevention of myocardial infarction.
Bibliography:Application Number: TW200897141714